Interestingly, ANT2 inhibition with RNAi induces a phenotypic modulation of cancer cells such as alterations in Fas, MHC class I, and ICAM-I expression levels, and sequentially, these modulations enhance anti-tumor immunity when combined with hMUC1 DNA vaccination. The gene discussed is SLC25A5; the disease is cancer.